The effect of estrogens and antiestrogens in a rat model for hot flush

• Published in: Maturitas Vol. 30; no. 3; pp. 307 - 316
• Main Authors: Merchenthaler, Istvan, Funkhouser, Judith M., Carver, Jeffrey M., Lundeen, Scott G., Ghosh, Krishnendu, Winneker, Richard C.
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 16.11.1998; Elsevier Science
• Subjects: Animals; Antiestrogens; Biological and medical sciences; Body Temperature - drug effects; Disease Models, Animal; Estrogen Antagonists - therapeutic use; Estrogens; Estrogens - agonists; Estrogens - therapeutic use; Female; Hormones. Endocrine system; Hot Flashes - drug therapy; Hot Flashes - metabolism; Hot flush; Medical sciences; Pharmacology. Drug treatments; Random Allocation; Rat model; Rats; Rats, Sprague-Dawley; Rat model; Antiestrogens; Estrogens; Hot flush; Agonist; Rat; Rodentia; Antiestrogen; Estrogen; Oral administration; Cardiovascular disease; Antihormone; Tamoxifene; Vascular disease; Vertebrata; Mammalia; Animal; Subcutaneous administration; Raloxifene; Antagonist; Non steroid compound; Hormonal receptor
• ISSN: 0378-5122; 1873-4111
• DOI: 10.1016/S0378-5122(98)00045-0

The present studies evaluated the effect of estrogens and the selective estrogen receptor modulator (SERM) tamoxifen and raloxifene in a rat model for hot flush. In this model, ovariectomized rats were treated for 8 or 9 days either sc or po. Rats were dependent to morphine by implanting a morphine pellet (75 mg each) sc on days 3 and 5 of treatment. On the last day of treatment, a thermistor, connected to a data acquisition system, was placed on the tail of each animal and morphine addiction was withdrawn by naloxone injection (1.0 mg/kg, sc). Temperature measurements were taken for 1 h under ketamine (80 mg/kg, im) anesthesia. In general, vehicle treated rats showed a 5–6°C elevation of their tail skin temperature with the peak occurring about 15 min after naloxone injection. 17 α-Ethinyl estradiol (EE) was evaluated both sc and po using a broad range of doses. The IC 50 for inhibition of tail skin temperature rise was approximately 0.1 mg/kg, sc and 0.2 mg/kg, po. 17 β-Estradiol and 17 α-estradiol were also active in this model whereas non-estrogenic steroids were inactive. Raloxifene and tamoxifen were tested for estrogen agonist and antagonist activity administered sc and po. Raloxifene did not demonstrate reproducible estrogen agonist activity at doses up to 10 mg/kg, whereas it demonstrated significant antagonistic activity at the 10 mg/kg dose regardless of the route of administration. Tamoxifen exhibited significant estrogen agonist activity at all doses tested (0.1–10.0 mg/kg) and was a significant antagonist of EE at the 1.0 mg/kg dose. Our results demonstrate the potential utility of this model to evaluate and discriminate among classes of compounds with varying degrees of estrogen agonist and antagonist activity.